Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DA85YQ
|
|||
| Drug Name |
TAK-341
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Multiple system atrophy [ICD-11: 8D87.0] | Phase 2 | [1] | |
| Company |
Takeda
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Synuclein alpha (SNCA) | Target Info | . | [2] |
| KEGG Pathway | Alzheimer's disease | |||
| Parkinson's disease | ||||
| NetPath Pathway | Leptin Signaling Pathway | |||
| RANKL Signaling Pathway | ||||
| Panther Pathway | Parkinson disease | |||
| Pathway Interaction Database | Alpha-synuclein signaling | |||
| Reactome | Amyloid formation | |||
| WikiPathways | Ectoderm Differentiation | |||
| Parkinsons Disease Pathway | ||||
| Parkin-Ubiquitin Proteasomal System pathway | ||||
| Alzheimers Disease | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05526391) A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy. U.S.National Institutes of Health. | |||
| REF 2 | Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol Dis. 2019 Dec;132:104582. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.